The collaboration will pair Evotec’s hit identification platform with LEO Pharma’s dermatology expertise in an aim to generate new leads against targets for a range of dermatological conditions.
A joint team of scientists from both Evotec and LEO Pharma will have access to Evotec’s high-value drug development and discovery absorption, distribution, metabolism, and excretion (ADME)-Tox services along with the company’s identification platform.
Evotec’s identification platform, according to the company, can be used through multiple platforms including virtual, biochemical, biophysical, and cell and phenotypic based screening with high-throughput capabilities.
Almirall, a skin-health focused pharmaceutical company, previously collaborated with Evotec to use the platform in a preclinical and drug discovery partnership.
At the time, Dr. Cord Dohrmann, chief scientific officer of Evotec said that the platform “enables disruption of cell signaling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities.”
Those drug discovery opportunities led to multiple collaborations. In October, Evotec used its drug discovery and development technology platform after entering an agreement with Sanofi to work on early-stage translational projects.
Stealth BioTherapeutics also tapped Evotec to conduct its preclinical and toxicology/safety studies for its lead candidate.